11/23/20 8:05 AMNasdaq : HALOHalozyme Raises Full Year 2020 GuidanceHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc.The Company is raising full year 2020 revenueRHEA-AIneutral
11/23/20 8:00 AMNasdaq : HALO, HZNPHorizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE(R) TechnologyHorizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE (R) drug delivery technology forRHEA-AIpositive
11/18/20 4:01 PMNasdaq : HALOHalozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare ConferenceHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside chat presentation for the Piper Sandler 32 nd Annual Virtual Healthcare Conference. The virtualRHEA-AIneutral
11/13/20 9:59 AMNasdaq : HALOHalozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo(R) (Fixed-Dose Combination Of Perjeta(R) And Herceptin(R) For Subcutaneous Injection) Utilizing Halozyme's ENHANZE(R) Technology For HER2-Positive Breast CancerHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Roche's Phesgo (R), a fixed-dose combination of Perjeta (R) (pertuzumab)RHEA-AIpositive
11/12/20 8:15 AMNasdaq : HALOHalozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO(TM)/ DARZALEX(R) Subcutaneous (SC) Formulation Utilizing ENHANZE(R) Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or ReHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of the daratumumabRHEA-AIpositive
11/05/20 8:15 AMNasdaq : HALOHalozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE(R)Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) daratumumab utilizing ENHANZE (R) will be the subject of presentations at the upcoming AmericanRHEA-AIneutral
11/02/20 4:01 PMNasdaq : HALOHalozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 GuidanceHalozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2020 and provided an update on its recent corporate activities and outlook. "I am pleased to report the first quarter of what the CompanyRHEA-AIpositive
10/22/20 8:00 AMNasdaq : HALOHalozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference CallHalozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2020 on Monday, November 2 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On theRHEA-AIneutral
10/06/20 2:14 AMNasdaq : HALOHalozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE(R) TechnologyHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019.Under the newly announced expansion, argenx gained the ability toRHEA-AIpositive
09/17/20 8:00 AMNasdaq : HALOHalozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze(R) In Non-Small Cell Lung CancerHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq (R)) for subcutaneous administration utilizing Halozyme'sRHEA-AIneutral
